SCHEMBL7260004

SCHEMBL7260004

COc1ccc(-c2cc(-c3ccccc3)[nH]n2)cc1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.87
MAPT P10636 5/20 0.87
NPC1 O15118 4/20 0.87
MAPK1 P28482 1/20 0.87
POLB P06746 1/20 0.71
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
KDM4E B2RXH2 4/20 0.68
NFKB1 P19838 3/20 0.68
NFKB2 Q00653 3/20 0.68
RELA Q04206 3/20 0.68
LMNA P02545 3/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
ALOX15 P16050 2/20 0.68
ADORA3 P0DMS8 1/20 0.68
ALOX12 P18054 1/20 0.68
HPGD P15428 3/20 0.62
GAA P10253 2/20 0.62
NPSR1 Q6W5P4 1/20 0.62
DYRK1A Q13627 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17279790 0.94 RAB9A (0.77) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL1181434 0.93 RAB9A (1.00) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL17279913 0.90 RAB9A (0.81) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL22307585 0.90 RAB9A (0.81) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL9976035 0.88 RAB9A (0.68) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL1181118 0.88 RAB9A (0.77) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL1181309 0.88 RAB9A (0.77) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL10358672 0.87 RAB9A (0.66) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL17279873 0.87 RAB9A (0.66) RAB9AMAPTNPC1MAPK1POLB
SCHEMBL14997979 0.87 RAB9A (0.87) RAB9AMAPTNPC1MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed
US-9867879-B2 Methods for use of small molecule activators of hem-Y / protoporphyrinogen oxidase (PPO) VANDERBILT UNIVERSITY (US) 2018-01-16 US disclosed
US-20160213780-A1 METHODS FOR USE OF SMALL MOLECULE ACTIVATORS OF HEM-Y / PROTOPORPHYRINOGEN OXIDASE (PPO) VANDERBILT UNIVERSITY 2016-07-28 US disclosed
WO-2003080616-A1 PYRAZOLOPYRIDAZINE DERIVATIVES, PROCESS FOR PREPARATION AND USE FOR THE INHIBITION OF GSK-3 GLAXO GROUP LIMITED (GB) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213780-A1 METHODS FOR USE OF SMALL MOLECULE ACTIVATORS OF HEM-Y / PROTOPORPHYRINOGEN OXIDASE (PPO) PPOX, HCCS, HMOX2 RAB9A 1246/4885MAPT 4774/4885NPC1 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.